Leap Therapeutics (LPTX) and Its Competitors Critical Survey

Leap Therapeutics (NASDAQ:LPTX) is one of 454 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its rivals? We will compare Leap Therapeutics to similar companies based on the strength of its earnings, risk, profitability, analyst recommendations, dividends, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Leap Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leap Therapeutics	1	0	0	0	1.00
Leap Therapeutics Competitors	4834	9976	16023	375	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 122.41%. Given Leap Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Leap Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Leap Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Leap Therapeutics	N/A	-247.44%	-146.51%
Leap Therapeutics Competitors	-2,626.20%	-359.54%	-43.35%

Institutional and Insider Ownership

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 39.3% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 4.3% of Leap Therapeutics shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Leap Therapeutics has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Leap Therapeutics’ rivals have a beta of 11.28, indicating that their average stock price is 1,028% more volatile than the S&P 500.

Earnings & Valuation

This table compares Leap Therapeutics and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Leap Therapeutics	N/A	-$67.56 million	-1.68
Leap Therapeutics Competitors	$435.56 million	-$68.47 million	-10.43

Leap Therapeutics’ rivals have higher revenue, but lower earnings than Leap Therapeutics. Leap Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Leap Therapeutics rivals beat Leap Therapeutics on 9 of the 13 factors compared.

About Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.